1.New series of WHO classification of tumors
China Oncology 2001;0(05):-
Since 2000,the new series WHO classification of tumors has been greatly changed. The name of the volumes altered from 《Histological Typing of Tumors》 to 《Pathology and Genetics of Tumors》.The series regards the type of tumor as a disease entity. A new approach to classification has been adopted. In this approach,all available information--morphology,immunophentype,genetic features, clinical features, and imaging features--is used to define a disease entity. Pathologist,oncologists and geneticists should be familiar to the new series WHO classification of tumors. The series provides an international standard. It will serve as an indispensable guide for the design of trials monitoring response to therpy and clinical outcome.
2.Clinicopathological features and management of gastrointestinal borderline lesion and correlative lesion
China Oncology 2001;0(05):-
One of the most problems is the diagnosis of the borderline lesion and/or borderline tumor to pathologists. It is necessary to make the correct diagnosis of the gastrointestinal borderline lesion and/or borderline tumor and correlative lesion such as gastrointestinal stromal tumors, gastrointestinal lymphoid proliferation and MALT lymphoma, IPSID, gastrointestinal adenoma and appendix carcinoid.[
3.Study on the clinical pathology of gastrointestinal stromal tumors
Cancer Research and Clinic 2006;0(08):-
The content of gastrointestinal stromal tumors had changed many times since the appearance of this idea. Along with the progress of molecular and biological study in recent years, it was a kind of tumor with specific clinical, pathological and molecular genetic characteristics, and was different from other specific tumors originated from the smooth muscle or nerves. Along with the success of targeted therapy of GIST, the disease was paid more attention. Therefore, a review of the clinical pathological study of GIST was needed.
4.Molecular and biologic study of gastrointestinal stromal tumors
Cancer Research and Clinic 2006;0(08):-
Gastrointestinal stromal tumors is a new kind of tumor known recently, especially the important progress in the molecular and biologic study of GIST were used quickly in the clinical diagnosis and treatment, and made a close combination of basic research and clinical applications. The study and application of target therapy of new molecules on the mechanism of molecular genetics of GIST was another successful example. Therefore, GIST was paid extensive attention by the scholars. The progress on the molecular and biological study was summarized.
5.Advances in research on extranodal NK/T cell lymphoma(nasal type)
China Oncology 2006;0(12):-
Extranodal NK/T cell lymphoma(nasal type) is a common,high malignant degree and poor prognosis entity of the nasal lymphoma.It is the most important to understand its genesis,development,clinical manifestation,pathologic diagnosis,therapy and prognosis.
8.Relationship between chromosomal translocation and synovial sarcoma
Yongkun WEI ; Jian WANG ; Xiongzeng ZHU ;
China Oncology 2001;0(05):-
Synovial sarcoma is a high grade malignant soft tissue tumor. Its diagnosis and differential diagnosis are difficult. In most cases the reciprocal chromosomal translocation between chromosome X and chromosome 18 could be found and characterized synovial sarcoma. This article reviewed the relationship between chromosomal translocation and the diagnosis, histological type and prognosis of synovial sarcoma.
9.Expression of P16 and CD44 in gastrointestinal stromal tumors and their relationship with the prognosis ;of patients
Enyi SHI ; Xiaoru WANG ; Xiaoning LI ; Xu CAI ; Xiongzeng ZHU
The Journal of Practical Medicine 2016;32(14):2333-2337
Objective To investigate the expression of P16 and CD44 in gastrointestinal stromal tumors (GIST) and their relationship with the prognosis of patients. Methods The GIST specimens of seventy patients who received surgical excision were collected. Tissue microarray of the seventy GIST samples was constructed. The expression of P16 and CD44 were detected by the immunohistochemical staining. The patients were followed up via out-patient examination and telephone. Results All the patients were followed up for 2-212 months, and the median time for follow-up was 68 months. The differences of the expression of P16 in GISTs among NIH risk ranks were insignificant (P > 0.05). The differences of the expression of CD44 in GISTs among NIH risk ranks were statistically significant (P < 0.05). Univariate analysis showed that tumor size, mitotic count, tumor location, NIH risk rank, the expression of P16 and CD44 were related to the prognosis of GIST patients. Multivariate showed that tumor size, mitotic count, tumor location, and the expression of CD44 was independent prognosis factors of GIST patients. Conclusion CD44 could be used as a biomarker in predicting the prognosis of GIST patients.
10.Benign glandular schwannoma
Xiang DU ; Xiongzeng ZHU ; Hongfen LU ; Al ET
China Oncology 2001;0(03):-
Purpose:To report a seldom case of benign glandular schwannoma and review its pathological characteristic. Methods:The tumor was observed by histology, histochemistry and immunohistochemistry. Results:Histologically, the tumor is composed of spindle cell component showing typical schwannoma and collections of glandular component with the expressions of Leu 7,GFAP,MBP,CEA,AE1/AE3 and 34?E12. Conclusions:The histogenesis of the glandular schwannoma remains uncertain. In our opinion, the glands within the tumor, when examined immunohistochemically, probably represent entrapped dermal appendageal glands with proliferation. [